

OAO PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED PROFIT AND LOSS STATEMENT
At 31 December 2008
(in US dollars and in thousands)

	Q4 2008	Q4 2007 Restated	FY 2008	FY 2007 Restated
Continuing operations				
Revenue	238 039	273 651	1 039 567	845 222
Cost of sales	(148 576)	(208 727)	(682 113)	(593 406)
Gross profit	89 463	64 923	357 454	251 816
Selling, general and administrative expenses	(82 425)	(113 428)	(348 603)	(304 548)
Impairment of goodwill	(23 350)	(1 704)	(23 350)	(1 704)
Share based payments expenses	1 057	(2 184)	842	(2 184)
Operating loss	(15 255)	(52 393)	(13 657)	(56 620)
Finance costs	(13 650)	(13 608)	(43 389)	(37 254)
Foreign currency exchange gain (loss)	(9 080)	(1 954)	(16 931)	(4 020)
Gain on sale of investment	(1 856)		15 072	
Other income (loss)	(230)	(4 080)	(1 019)	(3 550)
Loss before tax	(40 072)	(72 035)	(59 924)	(101 444)
Income tax expense	(3 616)	(2 533)	(12 900)	(9 344)
Loss for the year from continuing operations	(43 688)	(74 568)	(72 824)	(110 788)
Discontinued operations				
Profit for the year from discontinued operations	(165)	632	37 780	2 693
Loss for the year	(43 853)	(73 936)	(35 044)	(108 095)
Attributable to:				
Equity holders of the parent	(51 878)	(79 425)	(56 394)	(121 298)
Minority interest	8 027	5 487	21 350	13 203
	(43 853)	(73 936)	(35 044)	(108 095)

OA0 PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
At 31 December 2008
(in US dollars and in thousands)

	FY 2008	FY 2007 Restated
ASSETS		
NON-CURRENT ASSETS:		
Property, plant & equipment	112 905	187 544
Goodwill	168 000	246 839
Intangible assets	9 575	12 111
Other assets	1 271	1 752
Total non-current assets	291 751	448 246
CURRENT ASSETS:		
Inventories	112 569	172 696
Accounts receivable (net of bad debt provision)	103 736	105 319
Other receivables and prepaid expenses	53 613	51 256
Cash&Cash equivalents	23 899	32 887
Total current assets	293 817	362 158
TOTAL ASSETS	585 568	810 404
LIABILITIES AND SHAREHOLDERS' EQUITY		
SHAREHOLDERS' EQUITY:		
Share capital	198	198
Additional paid-in capital	120 103	120 103
Translation reserve	850	11 377
Retained earnings	(112 268)	(55 874)
Total shareholders' equity	8 883	75 804
MINORITY INTERESTS IN EQUITY OF SUBSIDIARIES	158 014	150 712
LONG-TERM LIABILITIES:		
Long-term debt	26 851	20 604
Share-based payment liability	-	963
Deferred tax liabilities	4 673	3397
Long term lease payable	342	982
Total long-term liabilities	31 866	25 946
CURRENT LIABILITIES:		
Trade accounts payable	206 535	201 482
Borrowings	122 541	271 381
Other payables and accrued expenses	35 020	51 810
Taxes payable	21 509	30 199
Current portion of share-based payments liability	-	1 313
Current portion of lease payable	1 200	1 757
Total current liabilities	386 805	557 942
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	585 568	810 404

OA0 PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
At 31 December 2008

	2008	2007 Restated
OPERATING ACTIVITIES		
Loss before tax from continuing and discontinued operations	(21 758)	(97 813)
Finance costs, net	43 406	36 888
Depreciation and amortization	21 448	20 370
Gain on disposal of subsidiaries	(35 435)	-
Gain on partial disposal of subsidiary	(15 072)	-
Impairment loss recognized on goodwill	23 350	1 704
Foreign exchange loss, net	16 280	4 020
Inventory written off	7 262	4 917
Change in allowance for doubtful debts and bad debts written off	1 456	9 163
Share-based payment (income) expense	(842)	2 184
Loss on disposal of property, plant and equipment	-	1 165
Change in unused vacation accrual	(580)	4 669
Loss on disposal of securities	-	775
Other non-cash expenses	2 111	206
Operating cash flow before working capital changes	41 626	(11 752)
Decrease (increase) in inventories	29 725	(53 308)
Increase in accounts receivable	(22 433)	(11 405)
Increase in other receivables and prepaid expenses	(20 908)	(22 206)
Increase in accounts payable	45 533	74 424
(Decrease) increase in other payables, accrued expenses and taxes payable	(5 443)	33 835
Cash generated from operations	68 100	9 588
Income taxes paid	(14 864)	(11 436)
Finance costs paid	(40 423)	(30 572)
Net cash generated by (used in) operating activities	12 813	(32 420)
INVESTING ACTIVITIES		
Net cash outflow on acquisition of subsidiaries	(12 856)	(87 630)
Purchase of property, plant and equipment	(11 963)	(33 566)
Purchase of intangible assets	(1 992)	(6 076)
Proceeds from sale of property, plant and equipment	2 479	344
Proceeds from partial disposal of subsidiary	35 497	-
Proceeds from disposal of subsidiaries, net of cash disposed	107 075	-
Net cash generated by (used in) investing activities	118 240	(126 928)
FINANCING ACTIVITIES		
Proceeds from borrowings	248 371	281 948
Repayments of borrowings	(378 407)	(295 521)
Proceeds from issuance of ordinary shares, net	-	106 628
Proceeds from consortium of investors	-	85 000
Distributions paid to minority shareholders	(2 534)	-
Net cash (used in) generated by financing activities	(132 570)	178 055
Effect of translation to presentation currency	(7 471)	1 211
Net (decrease) increase in cash and cash equivalents	(8 988)	19 918
Cash and cash equivalents at beginning of the year	32 887	12 969
Cash and cash equivalents at end of the year	23 899	32 887